Multiple Myeloma

Criteria to qualify for this study: Drug used in study:
  • Relapsed / Refractory
  • 2 part, multicenter, open label, phase 1a/1b study of TTI-622 in patients with advanced relapsed or refractory lymphoma and multiple myeloma

HR 56 TTI-622-01

A Phase 1a/1b dose escalation and expansion trial of TTI-622 in patients with Advanced Relapsed or Refractory Lymphoma or Myeloma.

https://clinicaltrials.gov/ct2/show/NCT03530683
Criteria to qualify for this study: Drug used in study:
  • Relapsed or refractory Multiple Myeloma or relapsed or refractory NHL; received at least 2 prior lines of therapy

HR 68

A phase I/II open-label, multi-center study to characterize the safety and tolerability of CFT7455 in subjects with relapsed/refractory Non-Hodgkin Lymphoma or Multiple Myeloma.

https://clinicaltrials.gov/ct2/results?cond=&term=NCT04756726
Criteria to qualify for this study: Drug used in study:
  • Relapsed or refractory MM after 3+ lines of therapy.

MM113

A Single-Arm, Open-Label, Phase 1 Study of the safety, efficacy, and Cellular Kinetics/Pharmacodynamics of Allo-715 to evaluate and Anti-BCMA Allogeneic CAR-T Cell Therapy in subjects with relapsed/refractory Multiple Myeloma.

https://clinicaltrials.gov/ct2/show/NCT04093596
Criteria to qualify for study: Drug used in study:
  • Newly diagnosed multiple myeloma with 4-8 cycles of induction and autologous stem cell transplant, archived bone marrow biopsy sample collected before induction or transplant.

MM 109

A randomized study of Daratumumab plus Lenalidomide vs. Lenalidomide alone as maintenance treatment in patients with newly diagnosed Multiple Myeloma who are minimal residual disease positive after frontline Autologous stem cell transplant.

https://clinicaltrials.gov/ct2/show/NCT03901963
Criteria to qualify for study: Drug used in study:
  • Received at least 2 cycles of initial therapy for MM

MM 117

A Multicenter, open-label, single arm Phase II study of Daratumumab as consolidation/maintenance therapy after Autologous Stem Cell Transplantation on patients with Multiple Myeloma.

https://clinicaltrials.gov/ct2/show/NCT03346135
Criteria to qualify for study: Drug used in study:
  • At least 3 prior lines of therapy (including proteasome inhibitor, immune modulatory drug, and an anti-CD38 antibody)

MM 121

A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Dose Expansion study of the safety, tolerability, and Pharmocokinetics of HPN217 in patients with Relapsed/Refractory Multiple Myeloma.

https://clinicaltrials.gov/ct2/show/NCT04184050
Criteria to qualify for study: Drug used in study:
  • At least 3 prior lines including a proteasome inhibitor, an immunomodulatory drug and an anti-CD38 drug; ECOG of 0 or 1

MM 127

A phase 1, multicenter, open label study of CC-95266 in subjects with relapsed and or refractory Multiple Myeloma.

https://clinicaltrials.gov/ct2/show/NCT04674813
Criteria to qualify for study: Drug used in study:
  • PENDING – 3 or more prior lines of therapy; ECOG of 0 or 1

MM 131

A multi-arm phase 1b study of Teclistamab with other anticancer therapies in participants with Multiple Myeloma.

https://clinicaltrials.gov/ct2/show/NCT04557098
Criteria to qualify for study: Drug used in study:
  • Symptomatic R/R MM; ECOG <1

MM 135

(SAR650984)In combination with Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone in patients with High-Risk Smoldering

https://clinicaltrials.gov/ct2/results?cond=&term=NCT04270409
Criteria to qualify for study: Drug used in study:
  • R/R MM after at least 2 prior lines; ECOG <2

MM 137

A Phase 1 study of FT576 as monotherapy and in combination with Daratumumab in subjects with Relapsed/Refractory Multiple Myeloma.

https://clinicaltrials.gov/ct2/results?cond=&term=NCT05182073
Criteria to qualify for study: Drug used in study:
  • R/R MM after at least 3 prior lines; ECOG<2

MM 138

A single arm, open-label, phase 1/2 study evaluating the safety, efficacy and cellular kinetics/ pharmacodynamics of ALLO-647 and ALLO-605, an Anti-BCMA Allogeneic CAR-T Cell Therapy in patients with relapsed/refractory Multiple Myeloma.

https://clinicaltrials.gov/ct2/results?cond=&term=NCT05000450
Criteria to qualify for study: Drug used in study:
  • R/R MM including treatment with a proteasome inhibitor, IMiD and Daratumumab; ECOG <1

MM 142

Open label, multi-center, Phase 1b/2 clinical trial to evaluate the safety and efficacy of autologous CAR-BCMA T Cells (CT053) in patients with relapsed and/or Refractory Multiple Myeloma

https://clinicaltrials.gov/ct2/results?cond=&term=NCT03915184
Criteria to qualify for study: Drug used in study:
  • R/R MM with no available therapies or intolerance to established therapies; ECOG <1

MM 143

An open label, multi-center, Phase 1b trial evaluating the safety, pharmacokinetics, and activity of Cevostamab in patients with Relapsed or Refractory Multiple Myeloma

https://clinicaltrials.gov/ct2/results?cond=&term=NCT04910568
Criteria to qualify for study: Drug used in study:
  • High-risk MM patients who complete pre transplant induction therapy

MM 144

Phase 2 study of Descartes-08 consolidation treatment in patients with high-risk Multiple Myeloma who have residual disease after induction therapy

https://clinicaltrials.gov/ct2/results?cond=&term=NCT04816526
Criteria to qualify for study: Drug used in study:
  • 2 or more prior lines of therapy; ECOG <1

MM 145

A multi-arm Phase 1b study of Talquetamab with other anticancer therapies in participants with Multiple Myeloma

https://clinicaltrials.gov/ct2/results?cond=&term=NCT05050097